Baird lowered the firm’s price target on Medtronic (MDT) to $100 from $103 and keeps a Neutral rating on the shares. The firm updated is model following results which showed its PFA share accekearted but 2027 sustainability is in question.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $100 from $105 at JPMorgan
- Medtronic resumed with an Outperform at Mizuho
- Medtronic: Solid Quarter but Limited Growth Visibility Justifies Hold Rating
- AtriCure price target lowered to $53 from $64 at Canaccord
- Medtronic price target raised to $118 from $116 at Barclays